Stay updated on Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.

Latest updates to the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.7%
- Check19 days agoChange DetectedDifference0.7%
- Check26 days agoChange DetectedThe webpage has undergone significant content removal regarding a Phase I/II study of Nivolumab in pediatric patients with relapsed/refractory acute myeloid leukemia, including detailed study protocols and inclusion/exclusion criteria. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference52%
- Check33 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.4%
- Check48 days agoChange DetectedDifference0.4%
- Check63 days agoChange DetectedDifference0.4%
Stay in the know with updates to Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.